vedolizumabVedolizumab64ustekinumabAzathioprineP19 inhibitorsP19 inhibitors51JAK inhibitors52ulcerative colitisCrohn’s diseaseInflammatory Bowel Disease+3 more
… restricted with only 50.7% of services reporting access.In CD, vedolizumab was accessible in 64/71 services (90.1%), including 31 (43.7%) …